Jan 22 (Reuters) - Moderna does not plan to invest in new late-stage vaccine trials because of growing opposition to ...

Check out the companies making headlines in midday trading. Fortinet — Shares jumped more than 7% after TD Cowen upgraded the ...

Moderna shares are down on Monday, pulling back following a recent report highlighting its latest cancer trial results.

In the Phase 2b trials, this combination therapy achieved a 49% decrease in the risk of recurrence or death relative to ...

January 26, 2026 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 ...

We learn what the findings could mean for fighting cancer ...

As the Trump administration erodes U.S. infrastructure supporting infectious disease vaccines, mRNA heavyweight Moderna plans ...

Five years ago, a group of high-risk skin cancer patients received a bespoke vaccine. The data is finally in, and the results ...

Equating lawful health incentives with corruption leaves parents wary, clinicians defensive and prevention efforts weakened, ...

Moderna (MRNA) stock hits a 52-week high to extend its YTD rally following back-to-back years of declines. Read more here.

Moderna Inc.’s chief executive officer said the company doesn’t plan to invest in new late-stage vaccine trials because of ...

Officials have confirmed bird flu in a backyard flock in Ottawa County, marking Michigan’s first case of the year.